Ablative Solutions: The company raised $91.4 million through a combination of Series D1 and Series D2 venture funding in a deal led by BioStar Capital and Gilde Healthcare Partners on June 13, 2022, putting the company’s pre-money valuation at $65 million. Michigan Accelerator Fund 1 and other undisclosed investors also participated in the round. The company is an operator of a clinical-stage medical device company intended to address the significant unmet clinical need for systemic hypertension.

Proximie: The company raised $80 million of Series C venture funding in a deal led by Advent Life Sciences on June 14, 2022. SoftBank Investment Advisers, The Impact Investors and 9 other investors also participated in the round. The company is a developer of a telehealth platform designed to share peer-to-peer live surgery assistance anywhere and at any time.

Aerin Medical: The company raised $60 million of Series F venture funding in a deal led by Ally Bridge Group on June 16, 2022. OrbiMed, KCK MedTech, Murphree Venture Partners, and Questa Capital also participated in the round. The company is a developer of a non-invasive treatment device designed to improve symptoms of nasal breathing disorders.

Elektrofi: The company raised $40 million of Series B venture funding in a deal led by Marshall Wace and BVF Partners on June 13, 2022, putting the company’s pre-money valuation at $80 million. Janus Henderson Investors, Logos Capital and other undisclosed investors also participated in the round. The funds will be used to establish a centralized GMP manufacturing line in support of multiple upcoming clinical trials. The company is an operator of a proprietary biotechnology platform for the delivery of biologics.

Sling Therapeutics: The company raised $35 million of Series A venture funding in a deal led by The Rise Fund on June 13, 2022, putting the company’s pre-money valuation at $50 million. Other undisclosed investors also participated in the round. The company is the developer of the oral small molecule linsitinib for thyroid eye disease (TED.

Artio Medical: The company raised $28 million of Series A venture funding from undisclosed investors on June 16, 2022. The company is a developer of medical devices designed to develop innovative products for the treatment of peripheral vascular, neurovascular, and structural heart diseases.

Onkos Surgical: The company raised $26.5 million of Series C venture funding from 3D Systems, 1315 Capital and Canaan Partners on June 16, 2022, putting the company’s pre-money valuation at $100 million. SV Health Investors also participated in the round. The company is a developer of precision orthopedics designed to reduce complexity and address the clinical challenges of musculoskeletal cancers and complex conditions.

Artizan Biosciences: The company raised $18.9 million of Series A2 venture funding in a deal led by Biohaven Pharmaceutical and Hatteras Venture Partners on June 15, 2022, putting the company’s pre-money valuation at $8.5 million. Brii Biosciences, AlleyCorp, Elm Street Ventures, Osage University Partners, and Connecticut Innovations also participated in the round. The company is a provider of pharmaceutical drug development services intended to address diseases involving microbiota in the human intestines.

TriFlo Cardiovascular: The company raised $13.8 million of Series A venture funding from undisclosed investors on June 16, 2022, putting the company’s pre-money valuation at $24 million. The company is an operator of a biotechnology firm focusing on an invasive transcatheter solution to treat tricuspid valve regurgitation.

MindImmune: The company raised $12.4 million of Series A venture funding from Pfizer Ventures, Dolby Family Ventures and Alzheimers Drug Discovery Foundation on June 14, 2022, putting the company’s pre-money valuation at $10 million. RightHill Ventures and Trend Venture also participated in the round. The company is a developer of first-in-class drugs designed to treat diseases of the central nervous system.

Adient Medical: The company raised $11.5 million of Series F venture funding from Cordis on June 14, 2022, putting the company’s pre-money valuation at $28.5 million. The company is a developer of absorbable medical devices designed for the prevention of pulmonary embolism in patients.

DermaSensor: The company raised $10 million of venture funding in a deal led by Ceros Capital Markets on June 15, 2022. The company is a developer of a skin cancer evaluation technology intended to provide cutting-edge spectroscopy and machine learning technologies to detect skin cancer early.

Cara Care: The company raised EUR 6.6 million of Series A venture funding in a deal led by Johnson & Johnson Innovation – JJDC, Dr. Schär and Asabys Partners on June 13, 2022. Atlantic Labs also participated in the round. The company is a developer of a virtual health advising application designed to help people with chronic digestive disorders.

Wonder Sciences: The company closed on $7 million of an undisclosed targeted amount of venture funding on June 15, 2022. The company is a developer of an online telemedicine platform designed for mental health and wellness.

Fibronostics: The company raised $6.5 million of Series A venture funding from undisclosed investors on June 15, 2022. The company is a developer of a non-invasive diagnostic testing system designed to provide algorithm-based health monitoring services.

eCovery: The company raised an undisclosed amount of venture funding in a deal led by VGH Versicherungen on June 16, 2022. Adesso and other undisclosed investors also participated in the round. The company is a developer of a digital healthcare platform designed to optimize the rehabilitation process for patients.

MediFox / ResMed: The company reached a definitive agreement to be acquired by ResMed (NYS: RMD) for an estimated EUR 1 billion on June 14, 2022. The acquisition builds on ResMed’s existing business in Germany as a provider of innovative cloud-connected medical devices that transform care for patients with sleep apnea and other respiratory conditions. The company is a developer of enterprise system software for outpatient care services, inpatient care facilities and therapeutic practices.

Excelera DCE / Future Health ESG Corp.: The company reached a definitive agreement to acquire Future Health ESG Corp. (NAS: FHLT) through a reverse merger, resulting in the combined entity trading on the NASDAQ Stock Exchange under the ticker symbol XLRA on June 14, 2022. The company is an operator of care delivery platform for medical practitioners.

Zura Bio / JATT Acquisition: The company has reached a definitive business combination agreement with JATT-Acquisition, resulting the combined entity trading on the NYSE under the ticker symbol ZURA on June 17, 2022. The company is an operator of a clinical-stage biotechnology company intended to advance ZB-168 in alopecia areata and other inflammatory diseases.

V.M.D. / Orion: The company was acquired by Orion (HEL: ORNAV) for an estimated EUR 130 million on June 15, 2022. The company is a manufacturer and distributor of veterinary medicine intended to offer products for the prevention and treatment of animal diseases.

Pega Medical / OrthoPediatrics: The company reached a definitive agreement to be acquired by OrthoPediatrics (NAS: KIDS) for $33 million on June 14, 2022. The total consideration consists of $31 million paid in cash and $2 million in stock. The company is a developer of osteosynthesis and deformity correction devices designed for patients suffering from osteogenesis imperfecta and other bone deformities.

1-800MD / One80 Intermediaries: The company was acquired by One80 Intermediaries, a subsidiary of Risk Strategies Company, for an undisclosed amount on June 14, 2022. The company is an operator of a network of telemedicine physicians across the United States specializing in convenient, quality medical care for individuals, families, employers, groups, and others.

Biomedical Diagnostics / Eurobio Scientific: The company, a subsidiary of Abviva, was acquired by Eurobio Scientific (PAR: ALERS) for an undisclosed amount on June 13, 2022. The company is a distributor of Vitro diagnostics products and instrumentation in the Benelux region.

Freedom Pathology Partners / EmeritusDX: The company was acquired by EmeritusDX for an undisclosed amount on June 13, 2022. The company is a provider of enhanced pathological diagnostic services.

Herbal Concepts / Ergode: The company was acquired by Ergode for an undisclosed amount on June 13, 2022. The company is a manufacturer of herbal wraps designed to provide physical comfort in cases of stress, tension, aches, pain, illness, or injury.

iDoc Telehealth Solutions / VSee: The company reached a definitive agreement to be acquired by VSee for an undisclosed amount on June 16, 2022. The company is a provider of neurocritical and intensive care telehealth services intended to offer access to medical care to patients when in need regardless of geographical limitations.

Intelligent Fingerprinting / GBS: The company reached a definitive agreement to be acquired by GBS for an undisclosed amount on June 16, 2022. The company is a developer of a drug screening system designed to offer fingerprinting drug tests.

PeerWell / Bardavon Health Innovations: The company was acquired by Bardavon Health Innovations for an undisclosed amount on June 14, 2022. The company is a developer of a surgery optimization platform designed to assist hip and knee replacement candidates.

Purilogics / Donaldson Company: The company was acquired by Donaldson Company (NYS: DCI) for an undisclosed amount on June 14, 2022. The company is a developer of disposable membrane chromatography columns designed to purify biologics for research and early-stage drug trials.

Revo Squared / Zomedica Pharmaceuticals: The company reached a definitive agreement to be acquired by Zomedica Pharmaceuticals (ASE: ZOM) for an undisclosed amount on June 15, 2022. The company is a manufacturer and developer of veterinary imaging systems catering to the needs of clinical veterinarians.

VSee / Digital Health Acquisition: The company reached a definitive agreement to combine with Digital Health Acquisition (NASDAQ:DHAC) through a reverse merger, resulting in the combined entity trading on the NASDAQ stock exchange under the ticker symbol VSEE on June 16, 2022. The company is a developer of an all-in-one telehealth platform designed to bring together clinical workflows and video communications.